Skip links

Digital Marketing Services for Biopharma Companies

Our biopharma marketing agency helps emerging biopharma companies, biologics manufacturers, and biosimilar brands build market visibility, educate prescribers and patients, and generate commercial results through compliant digital marketing strategies built for the specific demands of biological products.

Learn More
Contact Us
Pharmaceutical Brands 1@3X 100 Emulent
Emulent Marketing Proejct Reprocell E1722360186544 Emulent
Agno Emulent
Emulent Marketing Proejct Lubrizol Emulent
Emulent Marketing Proejct Altus Medical Equipment Emulent
Emulent Marketing Proejct Camargo Project Emulent
Premier Research Emulent

Our biopharma marketing agency thinks differently about how biologics and biosimilar companies build prescriber confidence, educate patients on complex therapies, and compete in a market where scientific credibility and regulatory compliance drive every marketing decision.

Marketing Challenges We Help Biopharma Brands Solve

Biopharma companies operate at the intersection of pharmaceutical regulation and biological science. Whether you are an emerging biopharma organization preparing to launch your first biologic, a biosimilar manufacturer competing against established reference products, or a commercial-stage company growing your prescriber base, these are the challenges we help you address:

Our biologic product is complex and prescribers do not fully understand it. We create clinical education content, mechanism-of-action visuals, and prescriber-focused resources that communicate how your biologic works, its clinical evidence, and its differentiation from existing treatments.

We are launching a biosimilar and need to overcome prescriber hesitation. We develop biosimilar education programs that address interchangeability questions, present switching study data, and build prescriber confidence through comparison content, FAQ resources, and clinical data summaries.

We are an emerging biopharma company with no brand recognition. We build digital presences that communicate pipeline value, scientific credibility, and commercial readiness to investors, partners, and future customers, even before your first product reaches the market.

Our patients struggle with access and affordability. We create patient-facing content that explains insurance coverage, patient assistance programs, specialty pharmacy processes, and cost savings, helping patients understand how to access your therapy.

We need to reach payers and formulary decision-makers. We develop payer-focused marketing materials that present health economic data, cost-effectiveness comparisons, and clinical value arguments designed for pharmacy benefit managers and health plan decision-makers.

Our digital marketing does not generate qualified HCP leads. We implement SEO, PPC, and content strategies that reach prescribers searching for treatment information, clinical data, and therapy comparisons in your therapeutic area.

We are preparing for a commercial product launch. We plan and execute phased launch campaigns that build pre-launch awareness, coordinate HCP and patient messaging at launch, and transition into ongoing marketing programs after launch.

We need real-world evidence to support our marketing claims. We develop content marketing programs built around real-world evidence (RWE) data, helping your brand communicate post-market outcomes, adherence data, and comparative effectiveness to prescribers and payers.

Pharmaceutical Brands_3@3X-100
Agno Emulent

Building a Unified Brand Identity for a Global Pharmaceutical CDMO After Acquisition

 Agno Pharma is a global contract development and manufacturing organization (CDMO) providing pharmaceutical development and manufacturing services. Following their acquisition of a US-based CDMO, they offer end-to-end solutions from formulation development through commercial manufacturing for pharmaceutical and biotech clients.

Industry: Pharmaceutical / CDMO (Contract Development and Manufacturing)

Type: Global Enterprise

Challenge: Agno Pharma was in the process of acquiring a US-based CDMO and needed a brand refresh that represented their new combined company. They required comprehensive services spanning website design, branding, SEO, and content creation to establish their new identity and drive growth.

Approach: Emulent provided full-service marketing support including:

  • We designed and developed their website through 3+ major updates as the company evolved post-acquisition.
  • We created a new logo and brand identity that represented the combined strengths of both organizations.
  • We implemented SEO optimization that helped the new brand rank for competitive pharmaceutical CDMO keywords.
  • We developed blog content that established thought leadership and attracted pharmaceutical companies seeking manufacturing partners.
  • We provided ongoing strategic guidance, becoming a trusted advisor who understood their brand as deeply as they did.

We are incredibly grateful for Bill and his team. Their expertise has been instrumental in our growth, from designing our website and logo to optimizing our SEO, creating compelling blog content, and offering great ideas.

Bill’s responsiveness and professionalism have made him a trusted partner for over three major website updates. He takes the time to truly understand our brand, ensuring that every project reflects our vision. We would not go anywhere else – if you’re looking for a dedicated team to assist with multiple aspects of your business, Bill and Emulent are the experts to work with!

Ingrid Schaper

Marketing Lead, Agno Pharma

30%+
SQLs
222%+
Organic Traffic
View More Client Stories

Biopharma SEO & Organic Search

Organic search is a primary research channel for HCPs evaluating biologic therapies and for patients learning about treatment options. We build SEO programs that target therapeutic area keywords, product comparison terms, and disease-state queries while meeting Google’s strict quality standards for medical content.

  • Therapeutic area SEO: keyword targeting for specific disease states, treatment protocols, and clinical decision points where prescribers and patients search for biologic therapy information
  • Biosimilar comparison SEO: content targeting reference biologic vs. biosimilar comparison queries, interchangeability searches, and switching-related questions
  • Technical SEO: site architecture for multi-product portfolios, schema markup for drug products and clinical data, mobile responsiveness, and Core Web Vitals
  • AI search visibility: positioning for ChatGPT, Perplexity, and Google AI Overviews where HCPs and patients increasingly discover therapy information
Pharmaceutical Brands Services Emulent
Pharmaceutical Brands Services Emulent

Biotech Website Design & Development

Your website is the single most important marketing asset for a biotechnology company. Investors, potential partners, regulatory agencies, job candidates, and customers all evaluate your company based on what they find on your site. We build biotech websites that serve multiple audiences without compromising scientific accuracy or professional presentation.

  • Pipeline and product pages: clear presentation of development stages, target indications, mechanisms of action, and clinical data for investor and partner audiences
  • Multi-audience architecture: separate content pathways for researchers, investors, HCPs, patients, and partners, with navigation designed for each audience’s priorities
  • CMS and technical development: WordPress, HubSpot, or custom CMS builds with content management workflows for regulated content
  • Conversion-focused design: demo request forms, contact capture, investor inquiry pathways, and calls-to-action tailored for B2B biotech sales cycles

Biopharma Website Design & Development

Your website serves prescribers seeking clinical data, patients researching treatment options, investors evaluating your pipeline, and partners assessing your commercial capabilities. We design biopharma websites that serve all of these audiences through clear architecture and compliant content.

  • Multi-audience design: separate pathways for HCPs, patients, investors, and partners with navigation and content tailored to each group’s priorities
  • Product and pipeline pages: clinical data presentation, indication information, mechanism-of-action content, and prescribing information access
  • Patient resources: treatment information pages, patient assistance program portals, specialty pharmacy guidance, and affordability tools
  • Compliance-ready CMS: content management systems with approval workflows for regulated content updates
Pharmaceutical Brands Services Emulent
Pharmaceutical Brands Services Emulent

Prescriber Education & HCP Marketing

Prescribers are the primary decision-makers for biologic therapies. We reach physicians, specialists, and other HCPs through targeted digital campaigns that provide the clinical evidence and educational content they need to prescribe with confidence.

  • Clinical education content: mechanism-of-action materials, clinical trial result summaries, real-world evidence presentations, and treatment protocol guides
  • Omnichannel HCP engagement: programmatic advertising by specialty, email campaigns with clinical updates, LinkedIn targeting, and webinar programs
  • Biosimilar prescriber programs: switching study data, interchangeability education, formulary transition guides, and FAQ resources designed in particular to address the concerns prescribers have about biosimilar products
  • KOL engagement: programs that connect your brand with respected specialists who can amplify your clinical messaging to their professional networks

Patient Marketing & Access Programs

Biologic therapies are among the most expensive medications available. Patient marketing for biopharma must go beyond awareness and actively help patients understand how to access and afford their treatment.

  • Disease awareness campaigns: unbranded education content about conditions treated by your biologic, designed to drive patients toward diagnosis and treatment conversations with their physicians
  • Patient access content: clear information about insurance coverage, prior authorization processes, specialty pharmacy enrollment, and patient assistance programs
  • Cost and affordability messaging: content that communicates biosimilar savings, copay assistance programs, and financial support resources
  • Compliance-first approach: all patient content includes fair balance, risk disclosure, and ISI as required by FDA regulations
Pharmaceutical Brands Services Emulent
Pharmaceutical Brands Services Emulent

PPC & Paid Media for Biopharma

Paid advertising accelerates visibility during product launches, formulary decision periods, and competitive market moments. We run compliant paid campaigns across search, social, and programmatic channels that target both HCPs and patients.

  • Search advertising: Google Ads targeting condition-specific, treatment comparison, and product-specific keywords with compliance-reviewed ad copy
  • Programmatic HCP targeting: display advertising on medical publications and clinical platforms, targeted by specialty and prescribing behavior
  • LinkedIn campaigns: B2B advertising targeting healthcare executives, medical directors, and formulary decision-makers
  • Patient audience targeting: compliant social media and display campaigns reaching patients researching specific conditions and treatments

Biopharma Marketing Stats

  1. The global biosimilars market is projected to reach $100 billion by 2030.
  2. Biologic drugs account for over 40% of total U.S. prescription drug spending.
  3. Biosimilars can reduce costs by 15-40% compared to reference biologics.
  4. 71% of HCPs prefer digital interactions when learning about new therapies.
  5. Personalized HCP content increases engagement by 56% compared to generic messaging.
  6. Disease awareness campaigns improve patient-physician conversations by 28%.
  7. Specialty pharmacy utilization for biologics has grown 12% year-over-year.
  8. Multichannel biopharma campaigns see 43% higher HCP engagement rates.
  9. Real-world evidence content generates 2x more prescriber engagement than promotional content alone.
  10. FDA approved 12 new biosimilars in 2024, increasing market competition significantly.
  11. Patient assistance program awareness campaigns improve therapy access by 25%.
  12. Digital channels now account for over 70% of healthcare advertising spend.
  13. Biopharma companies that publish educational content see 3x more website engagement.
  14. Email marketing to HCPs delivers an average 38% open rate when targeted by specialty.
  15. Formulary-focused marketing materials improve payer decision timelines by 20%.

Sources: IQVIA, McKinsey, MM+M, FDA, Statista

Pharmaceutical Brands Services Emulent
Faqs Emulent Emulent

Biopharma Digital Marketing FAQs

What is the difference between pharmaceutical marketing and biopharma marketing?

Biopharma marketing focuses on products derived from living organisms (biologics and biosimilars), which are more complex than traditional small-molecule drugs. This complexity affects how products are explained to prescribers, how patients understand their treatment, and how companies communicate clinical data. Marketing strategies must address biologics-specific concerns like biosimilar interchangeability, specialty pharmacy processes, and higher product costs.

Can you help with biosimilar launch marketing?

Yes. Biosimilar launches require a specific approach that includes prescriber education, formulary positioning support, patient access messaging, and competitive differentiation against the reference biologic. We build launch campaigns that address each of these areas through coordinated digital channels.

Do you work with emerging biopharma companies that do not have commercial products yet?

Yes. We work with pre-commercial biopharma companies to build investor-ready digital presences, develop pipeline communication content, and create the brand foundation needed for a successful commercial launch when your product reaches the market.

How do you handle the compliance requirements for biologic product marketing?

We build all content with regulatory review in mind. Our process includes compliance checkpoints at every stage of content development, and we coordinate with your MLR team to confirm that all claims are supported by approved data. We are experienced with FDA fair balance requirements, ISI presentation, and the specific rules governing branded and unbranded biologic product promotion.

Can you support both HCP and patient marketing?

Yes. We build integrated programs that include HCP-focused campaigns (clinical education, prescriber targeting, KOL programs) and patient-facing campaigns (disease awareness, access information, affordability content). Both tracks are coordinated to create a consistent brand experience across audiences.